Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03629236 · ClinicalTrials.gov registry record · NA
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
A NA study of Venous Leg Ulcer, sponsored by Osiris Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT03629236: Completed NA study of Venous Leg Ulcer, sponsored by Osiris Therapeutics.
NCT03629236 is a NA study of Venous Leg Ulcer that has completed, run by Osiris Therapeutics. The registered enrollment target is 200 participants, below the 239-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (16% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03629236, a NA study of Venous Leg Ulcer, has completed, sponsored by Osiris Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs
Conditions Studied
Interventions
- OTHER Control
- OTHER GrafixPL
Study Locations (2)
Florida
- Integral Clinical Trial Solutions - Doral
Massachusetts
- SSH - Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2021-06-24 |
| Phase | NA |
What the finished NCT03629236 record still lists
NCT03629236 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 239-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT03629236 reports a single indexed study location in Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03629236 about?
NCT03629236 is a clinical study titled "Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers". A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs
What is the current status of trial NCT03629236?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2018-06-27. Estimated completion is 2021-06-24.
What conditions does trial NCT03629236 study?
This clinical trial studies the following conditions: Venous Leg Ulcer.
What interventions are being tested in trial NCT03629236?
The interventions under investigation include: Control (OTHER), GrafixPL (OTHER).
Who is sponsoring clinical trial NCT03629236?
This trial is sponsored by Osiris Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03629236 being conducted?
This trial has 2 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Leg Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03629236's enrollment target sits among peer trials
200 12th of 35 higher than 24 of 35 other Venous Leg Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
RECRUITING · NA
-
INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone
RECRUITING · NA
-
A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI